Prestige Consumer Healthcare Inc. (PBH) reported Q4 2026 results showing revenue of $281.6 million, down 5.0% year-over-year, while gross profit fell to $146.3 million (-14.0% YoY) and operating profit declined to $75.5 million (-14.6% YoY). Net income attributable to common shareholders rose to $53.9 million (+7.6% YoY) and diluted earnings per share increased to $1.13 (+13.0% YoY).
Key quarterly figures:
Cash flow and balance-sheet highlights:
Compared with analyst expectations, revenue missed the estimate of $296.7 million, and diluted EPS came in below the estimate of $1.40, reflecting softer top-line performance despite the rise in net income and EPS year-over-year.
Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.
Prestige Consumer Healthcare Inc. Insider Trading Activity
Prestige Consumer Healthcare Inc. insiders have traded $PBH stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $PBH stock by insiders over the last 6 months:
- JEFFREY ZERILLO (Senior VP Operations) has made 0 purchases and 4 sales selling 2,346 shares for an estimated $145,070.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Prestige Consumer Healthcare Inc. Hedge Fund Activity
We have seen 155 institutional investors add shares of Prestige Consumer Healthcare Inc. stock to their portfolio, and 207 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MACQUARIE GROUP LTD removed 1,620,912 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $99,994,061
- FMR LLC removed 652,734 shares (-89.0%) from their portfolio in Q4 2025, for an estimated $40,267,160
- ARIEL INVESTMENTS, LLC added 507,538 shares (+14.1%) to their portfolio in Q4 2025, for an estimated $31,310,019
- CAPITAL RESEARCH GLOBAL INVESTORS added 333,182 shares (+59.3%) to their portfolio in Q1 2026, for an estimated $19,747,697
- BRANDES INVESTMENT PARTNERS, LP added 292,744 shares (+93.2%) to their portfolio in Q4 2025, for an estimated $18,059,377
- BLACKROCK, INC. removed 273,564 shares (-3.6%) from their portfolio in Q1 2026, for an estimated $16,214,138
- JPMORGAN CHASE & CO removed 229,722 shares (-50.0%) from their portfolio in Q4 2025, for an estimated $14,171,550
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Prestige Consumer Healthcare Inc. Analyst Ratings
Wall Street analysts have issued reports on $PBH in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Scotiabank issued a "Sector Outperform" rating on 12/18/2025
To track analyst ratings and price targets for Prestige Consumer Healthcare Inc., check out Quiver Quantitative's $PBH forecast page.
Prestige Consumer Healthcare Inc. Price Targets
Multiple analysts have issued price targets for $PBH recently. We have seen 4 analysts offer price targets for $PBH in the last 6 months, with a median target of $83.0.
Here are some recent targets:
- Rupesh Parikh from Oppenheimer set a target price of $65.0 on 05/07/2026
- John Zamparo from Scotiabank set a target price of $100.0 on 03/20/2026
- Ryland Conrad from RBC Capital set a target price of $129.0 on 03/20/2026
- Keith Devas from Jefferies set a target price of $66.0 on 02/02/2026
